Church Kevin's most recent trade in Athira Pharma Inc was a trade of 36,666 Restricted Stock Units done . Disclosure was reported to the exchange on June 30, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Athira Pharma Inc | Kevin Church | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2025 | 36,666 | 36,667 | - | - | Restricted Stock Units | |
Athira Pharma Inc | Kevin Church | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2025 | 36,666 | 177,427 | - | 0 | Common Stock | |
Athira Pharma Inc | Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.23 per share. | 30 Jun 2025 | 10,000 | 140,761 | - | 0.2 | 2,312 | Common Stock |
Athira Pharma Inc | Kevin Church | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 0.29 per share. | 30 Jun 2025 | 8,526 | 168,901 | - | 0.3 | 2,502 | Common Stock |
Athira Pharma Inc | Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 87,845 | 87,845 | - | - | Stock Option (Right to Buy) | |
Athira Pharma Inc | Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 58,563 | 58,563 | - | - | Restricted Stock Units | |
Athira Pharma Inc | Kevin Church | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 36,667 | 139,271 | - | 0 | Common Stock | |
Athira Pharma Inc | Kevin Church | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 36,667 | 73,333 | - | - | Restricted Stock Units | |
Athira Pharma Inc | Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.55 per share. | 31 Dec 2024 | 9,920 | 102,604 | - | 0.6 | 5,456 | Common Stock |
Athira Pharma Inc | Kevin Church | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 0.56 per share. | 31 Dec 2024 | 8,510 | 130,761 | - | 0.6 | 4,782 | Common Stock |
Athira Pharma Inc | Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
Athira Pharma Inc | Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 110,000 | 110,000 | - | - | Restricted Stock Units | |
Athira Pharma Inc | Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 10,000 | 95,209 | - | 0 | Common Stock | |
Athira Pharma Inc | Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 1.34 per share. | 03 Sep 2024 | 4,953 | 85,209 | - | 1.3 | 6,637 | Common Stock |
Athira Pharma Inc | Kevin Church | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 03 Sep 2024 | 2,525 | 92,684 | - | 0.6 | 1,429 | Common Stock |
Athira Pharma Inc | Church Kevin | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 220,000 | 220,000 | - | - | Stock Option (Right to Buy) | |
Athira Pharma Inc | Kevin Church | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 10,000 | 82,668 | - | 0 | Common Stock | |
Athira Pharma Inc | Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 10,000 | 82,668 | - | 0 | Common Stock | |
Athira Pharma Inc | Church Kevin | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 1.34 per share. | 04 Jan 2024 | 3,397 | 72,668 | - | 1.3 | 4,552 | Common Stock |
Athira Pharma Inc | Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 1.34 per share. | 04 Jan 2024 | 3,397 | 72,668 | - | 1.3 | 4,552 | Common Stock |
Athira Pharma Inc | Kevin Church | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 2,412 | 80,256 | - | 2.9 | 7,019 | Common Stock |
Athira Pharma Inc | Church Kevin | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 2,412 | 80,256 | - | 2.9 | 7,019 | Common Stock |
Athira Pharma Inc | Kevin Church | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 2.41 per share. | 04 Jan 2024 | 809 | 69,271 | - | 2.4 | 1,950 | Common Stock |
Athira Pharma Inc | Church Kevin | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 2.41 per share. | 04 Jan 2024 | 809 | 69,271 | - | 2.4 | 1,950 | Common Stock |
Athira Pharma Inc | Kevin Church | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 24 Mar 2023 | 6,410 | 68,462 | - | 1.4 | 8,654 | Common Stock |
Athira Pharma Inc | Kevin Church | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2023 | 6,410 | 0 | - | - | Stock Option (Right to Buy) | |
Athira Pharma Inc | Kevin Church | Executive VP, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
Athira Pharma Inc | Kevin Church | Executive VP, Research | Grant, award, or other acquisition of securities at price $ 2.74 per share. | 19 Jan 2023 | 657 | 62,052 | - | 2.7 | 1,800 | Common Stock |
Athira Pharma Inc | Kevin Church | Executive VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2022 | 3,700 | 6,410 | - | - | Stock Option (Right to Buy) | |
Athira Pharma Inc | Kevin Church | Executive VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 28 Oct 2022 | 3,700 | 61,395 | - | 1.4 | 4,995 | Common Stock |
Athira Pharma Inc | Kevin Church | Executive VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 08 Jun 2022 | 2,500 | 50,309 | - | 1.4 | 3,375 | Common Stock |
Athira Pharma Inc | Kevin Church | Executive VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2022 | 2,500 | 10,110 | - | - | Stock Option (Right to Buy) | |
Athira Pharma Inc | Kevin Church | Executive VP, Research | Grant, award, or other acquisition of securities at price $ 7.06 per share. | 08 Jun 2022 | 243 | 47,809 | - | 7.1 | 1,716 | Common Stock |
Athira Pharma Inc | Kevin Church | Executive VP, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
Athira Pharma Inc | Kevin Church | Executive VP, Research | Grant, award, or other acquisition of securities at price $ 12.51 per share. | 18 Jan 2022 | 96 | 44,414 | - | 12.5 | 1,201 | Common Stock |
Cyclerion Therapeutics Inc | Kevin Churchwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
Athira Pharma Inc | Kevin Church | Vice President of Discovery | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 3,152 | 0 | - | - | Stock Option (Right to Buy) | |
Athira Pharma Inc | Kevin Church | Vice President of Discovery | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.04 per share. | 18 May 2021 | 3,152 | 44,318 | - | 1.0 | 3,278 | Common Stock |
Athira Pharma Inc | Kevin Church | Vice President of Discovery | Grant, award, or other acquisition of securities at price $ 14.45 per share. | 18 May 2021 | 185 | 41,166 | - | 14.4 | 2,673 | Common Stock |
Athira Pharma Inc | Kevin Church | Vice President of Discovery | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) |